Mechanisms Responsible for Hypoglycemia Associated Autonomic Failure (HAAF)

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Ilan Gabriely, M.D., Albert Einstein College of Medicine of Yeshiva University
ClinicalTrials.gov Identifier:
NCT00678145
First received: May 14, 2008
Last updated: July 24, 2013
Last verified: July 2013
  Purpose

Many studies have demonstrated that when people with diabetes are intensively treated with insulin in order to maintain their glucose within the normal range, all the complications of diabetes can be prevented or delayed. However, such treatment carries a significant risk of severe hypoglycemia (excessively low blood glucose levels), which may be life-threatening. Thus, ideal treatment with insulin in patients with diabetes can be seen as a double-edged sword: intensive treatment will delay the complications but is also associated with an increased risk of disabling hypoglycemia. In normal conditions, when hypoglycemia occurs, the body responds by secreting a variety of hormones and by activating the autonomous nervous system which ultimately will result in increasing the blood glucose to normal levels. Patients with diabetes, lose this capacity to effectively respond to hypoglycemia and become more susceptible to a fall in plasma glucose. Paradoxically, repeated episodes of hypoglycemia—especially in the most vulnerable persons with type 1 who need insulin for life--induce a metabolic deterioration that further increases the risk of developing hypoglycemia.

Our proposal focuses on understanding the mechanisms the body uses in order to respond to hypoglycemia and on potential tools (medicines) that may be used in order to prevent this metabolic deterioration associated with repeated episodes of hypoglycemia.

Based on previous data generated in our laboratory (and others), we propose that repeated episodes of hypoglycemia are associated with a deterioration in the "body sensor" for hypoglycemia in diabetes. Moreover, since many studies have shown that such deterioration in the response to hypoglycemia can be induced also by exercise (patients with diabetes are at greater risk for hypoglycemia after exercise), we propose that exercise (and other stresses) affect the hypoglycemia response by endorphin release (endorphins are proteins responsible for inhibition of the neuroendocrine response system).

Developing a method that will decrease the incidence of severe hypoglycemia will result in safer control of blood glucose, a decrease in the complications of diabetes, and ultimately in a better quality and longer life for many patients with diabetes.


Condition Intervention
Diabetes Mellitus
Hypoglycemia
Autonomic Failure
Drug: naloxone
Dietary Supplement: fructose
Behavioral: exercise

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Mechanisms of Hypoglycemia Associated Autonomic Failure

Resource links provided by NLM:


Further study details as provided by Albert Einstein College of Medicine of Yeshiva University:

Primary Outcome Measures:
  • Change in the counterregulatory responses to hypoglycemia compared to controls [ Time Frame: Next day after the intervention ] [ Designated as safety issue: No ]

Enrollment: 116
Study Start Date: March 2008
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Healthy individuals and patients with type 1 diabetes mellitus
Drug: naloxone
Administering fructose or naloxone or exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
Other Name: Narcan
Dietary Supplement: fructose
Administering fructose or naloxone or exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
Other Name: Insulin
Behavioral: exercise
Administering fructose or naloxone or exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.

Detailed Description:

Severe hypoglycemia (SH) is the major limitation of intensive insulin treatment in type 1 diabetes (T1DM), and the near-term prospects for perfected insulin therapy without this risk are dim. Intensively treated T1DM patients suffer from impaired counterregulation of hypoglycemia (HYPO)—ie, HYPO-Associated Autonomic Failure (HAAF) and HYPO unawareness (HU)—which enhance their susceptibility to SH. The precise mechanisms of HAAF and HU, however, have not been clarified, though multiple redundant control systems are implicated. Experimental HYPO and exercise in normal and T1DM subjects reproduce HAAF and HU, providing a robust experimental paradigm of these disorders. We have shown that fructose, infused in a catalytic dose for modulating glucokinase activity, results in augmentation of the counterregulatory responses to HYPO in nondiabetic and in T1DM individuals. We hypothesize that an equivalent infusion of fructose will prevent HAAF in nondiabetic and in T1DM persons. Furthermore, since both HYPO and exercise are associated with endogenous opioid (EO) release, and blocking EO improves HYPO counterregulation, we hypothesize that repeated HYPO episodes induce alterations in the modulatory effects of EO on hormonal and glucose counterregulation, ultimately leading to HAAF. We also propose that HYPO autoregulation, and hepatic glycogen metabolism play important roles in the development of HAAF and HU. The specific aims are: 1) to determine the effects of previous modulation of glucokinase activity on the counterregulatory hormonal and glucose recovery responses to subsequent HYPO in nondiabetic and T1DM subjects, 2) to examine the effects of blocking the inhibitory action of endorphins on the central neuroendocrine response system (with naloxone), during recurrent HYPO or exercise, on subsequent HYPO counterregulatory responses in nondiabetic and T1DM subjects, 3) to analyze the effects of recurrent mild HYPO (autoregulation), on subsequent HYPO counterregulation in nondiabetic and in T1DM subjects, and 4) to determine the effects of recurrent HYPO on hepatic glycogen content in nondiabetic and T1DM subjects, and the effects of normalization of liver glycogen content, by means of insulin and glucose administration, on experimental HAAF in T1DM subjects.

  Eligibility

Ages Eligible for Study:   19 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Non-diabetic individuals
  • Patients with type 1 diabetes mellitus

Exclusion Criteria:

  • Pregnant or planning to get pregnant women
  • Breast-feeding women
  • Children
  • Subjects taking pain killers or drug addicts
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00678145

Locations
United States, New York
Albert Einstein College of Medicine / General Clinical Research Center
Bronx, New York, United States, 10461
Sponsors and Collaborators
Albert Einstein College of Medicine of Yeshiva University
Investigators
Principal Investigator: Ilan Gabriely, M.D. Albert Einstein College of Medicine of Yeshiva University
  More Information

No publications provided by Albert Einstein College of Medicine of Yeshiva University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ilan Gabriely, M.D., M.D., Albert Einstein College of Medicine of Yeshiva University
ClinicalTrials.gov Identifier: NCT00678145     History of Changes
Other Study ID Numbers: 2008-202, R01 DK079974-01
Study First Received: May 14, 2008
Last Updated: July 24, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Albert Einstein College of Medicine of Yeshiva University:
Diabetes
Hypoglycemia
HAAF
Counterregulation

Additional relevant MeSH terms:
Diabetes Mellitus
Hypoglycemia
Pure Autonomic Failure
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Primary Dysautonomias
Autonomic Nervous System Diseases
Nervous System Diseases
Naloxone
Narcotic Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 21, 2014